Chugai (TYO: 4519) has concluded a new license agreement with Swiss pharma giant Roche (ROG: SIX), which owns around 62% of the Japanese drugmaker .
Chugai will gain rights to develop RG6631, the anti-TL1A antibody, currently in development for ulcerative colitis and Crohn’s disease in Japan. In return, Roche will receive an undisclosed upfront fee and milestone payments.
“Ulcerative colitis and Crohn’s disease are intractable conditions characterized by cycles of remission and relapse. The recurring symptoms such as diarrhea and abdominal pain often restrict daily life, requiring long-term hospital visits, and the risk of developing colon cancer increases as the disease progresses1. In addition, treatment methods to maintain remission have not been sufficiently established, and there remains a significant unmet need. Chugai will work closely with Roche to bring RG6631 to patients with Ulcerative colitis and Crohn’s disease as soon as possible,” said Chugai’s president and chief executive, Dr Osamu Okuda.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze